Senate Bill 2308 | Effective: 6-11-25 |
Senate Author: Parker et al. | Senate Committee: Health & Human Services |
House Sponsor: Harris et al. | House Committee: Public Health |
Senate Bill 2308 amends the Health and Safety Code to provide for the creation of a consortium that may apply for Health and Human Services Commission (HHSC) selection to conduct drug development clinical trials with ibogaine and secure FDA approval of ibogaine as a medication for the treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health condition for which ibogaine demonstrates efficacy. Among other provisions, the bill sets out requirements regarding a consortium's composition and administration by a lead institution of higher education, HHSC's selection of a consortium and contract with the lead institution, the allocation of revenue attributable to intellectual property rights and other commercial rights arising from the clinical trials, and a prescribing physician's supervision of ibogaine administration.